Eli Lilly’s star oral GLP-1 candidate orforglipron and Novo Nordisk’s Wegovy (semaglutide) were named voucher winners in a ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t ...

Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO the inflammation biotech will use to ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

China is set to ease restrictions on some Illumina products, giving the sequencing giant a partial reprieve. | China is set to ease restrictions on some Illumina products, giving the sequencing giant ...

More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs. | More ...

Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech ...

Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the ...